Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown. Patients and Methods ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Both hand cooling and hand compression reduced the incidence of grade 2 or higher chemotherapy-induced peripheral neuropathy ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

Genomic assays play a critical role in guiding treatment decisions for patients with early-stage invasive breast cancer by ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) has found that the tumor ...

Patients accrued to ABCSG-12, the only trial to include premenopausal women, were all treated with gonadotropin-releasing hormone agonist therapy to achieve a postmenopausal state. 22 Eligible ...